Did you know that there are over 200 different types of cancer known to humankind? Such a diagnosis is heartbreaking, seeing as the treatment type is greatly dependent on how far the cancer has spread throughout the body. As we all know, when it is constrained to a specific region in the earlier stages, specialists have some control. Otherwise, even a round of chemotherapy is unlikely to do wonders. For those of you wondering why a cure hasn’t been discovered despite the advancement in technology, a tiny biotech company has supposedly developed what’s known as “Smart Chemo,” which is anticipated to revolutionize cancer treatment.
The Wall Street Journal describes Smart Chemo as “like a guided missile for cancer,” while The Journal Nature calls it “the dawn of a new era against cancer.” What distinguishes this breakthrough is that it is a drop of liquid that only attacks cancer cells and leaves the healthy ones untouched. Chemotherapy, on the other hand, is less appealing because it attacks all cells. Ever since the FDA fast-tracked approval for this tiny company, drug companies such as Pfizer, Merck, Bristol-Myers, and AbbVie have invested billions.
According to investor and editor Dylan Jovine, here are the key points to know about Smart Chemo:
- It has the potential to eliminate the side effects of cancer treatment, making it a safer and more effective option
- It could be used to treat an array of cancer types
- It could potentially “cut the rate of death in women with a type of advanced breast cancer by one-third”
- This opportunity might react like that of Immunogen (resulting in a 430% gain)
- It could one day become a prime takeover company for a large pharmaceutical company
All this is to say that society is finally making headway toward putting a stop to cancer deaths. The win-win situation is that those who invest in this opportunity are likely to witness a financial gain, especially as the tiny company has advanced in its trials (persuading the FDA). So, how does one start building a position in this tiny company? Here’s where it is imperative to introduce Behind the Markets.
What is Behind the Markets?
Behind the Markets is an independent financial advisory where lead editor, Dylan Jovine will share his top investment finds. This product focuses on a growth strategy: identifying and holding small, under-the-radar companies that are at the forefront of tremendous changes. For the investor, this means investing in companies that outperform competition in terms of innovation and revenue, but have yet to see gains in stock price. Our editorial team discovered that Behind the Markets typically targets mid-cap/medium-term companies (or market capitalizations ranging from $1 billion to $10 billion) with a high return-on-equity (ROE), little debt, and a sustainable competitive advantage. With the introduction out of the way, let’s take a closer look at the incentives for joining Behind the Markets.
What’s presently offered through the Behind the Markets membership?
Based on the introduction, individuals should have gathered that joining Behind the Markets will guarantee intel into Smart Chemo. Dylan is offering the following resources to get everyone started on their investment journey:
Special Report #1: Smart Chemo – The Small Biotech Revolutionizing Cancer Treatment
Inside this special 100-page report, Dylan claims to have laid out every inch of detail on Smart Chemo and its creators. In particular, we are possibly looking at the opinions of leading scientists on the discovery, the pros and cons of investing in Smart Chemo, how to create a position, and possible obstacles that the company might face. Regarding the latter, the only obstacle Dylan sees is a takeover, which, though it will help the stock, might not be to the extent that one might be hoping. In addition to his main pick, Dylan claims to have added another biotech recommendation that he believes has a lot to offer when it comes to transforming cancer treatment.
Join Behind the Markets today!
Besides the above-listed resource, members are entitled to the following incentives:
- 12 monthly issues of Behind the Markets, each covering one to two recommendations accompanied by a 30-page analysis report
- Buy and sell alerts as soon as a stock is in an uptrend
- Unlimited access to the Behind the Markets members’ website filled with past and present alerts, bonus reports, open/hold/closed stocks, updates, and informative articles
- Access to the Behind the Markets VIP concierge service (Monday through Friday from 9 a.m. to 5 p.m. EST)
- 30-day money-back guarantee, allowing members to read over and test Dylan’s track before fully investing
How much does Behind the Markets cost?
It depends on the type of membership that individuals wish to purchase. At present, Dylan is offering one of three types, as summarized below:
- Good Offer ($49 yearly):
Immediate access to Behind the Markets
Special Report #1: Smart Chemo – The Small Biotech Revolutionizing Cancer Treatment
- Great Offer ($99 yearly):
Everything from the Good Offer
Bonus Report #1: The Small Company Revolutionizing Medicine
Bonus Report #2: 4 Companies Using Radical Methods to Fight Alzheimer’s, Parkinson’s, and Dementia
Bonus Report #3: 3 Companies at the Forefront of the Weight-Loss Revolution
- Best Offer ($99 yearly):
Everything from the Great Offer
Bonus Report #4: The AI Company Revolutionizing Medicine
Bonus Report #5: How to Generate Monthly Income from Your Biotech Portfolio
Bonus Report #6: 3 Ingredients to Pick Great Biotech Stocks
Don’t miss out on these bonuses!
As for the 30-day money-back guarantee, individuals have 30 days from the date of purchase to decide whether to continue or discontinue their membership. To learn more about the refund policy, consider reaching out to customer support in one of the following ways:
- Phone: 1 (800) 851-1965
- Email: newsletters@behindthemarkets.com
- Mailing address: Behind the Markets, 4260 NW 1st Avenue, Suite # 55, Boca Raton, FL 33431 – 4264
Meet Dylan Jovine
Dylan Jovine is the founder, CEO, and editor of several Behind the Markets products. Before having reached this height, Dylan claims to have taken the average route, starting on Wall Street in 1991 and eventually finding his break from Wall Street outsider Peter Jacquith. Peter Jacquith is a banker who supposedly became popular after saving New York City from bankruptcy in the 1970s. After leaving Lazard Freres & Company, Peter started his own boutique, which was where Dylan learned the ins and outs of studying stocks and managing accounts. Truthfully, it only took him three years to earn the reputation for “picking stocks right before they were taken over.”
During the financial crisis of 2008-2009, Dylan simply said, “The stock market at 6,500 is like walking into your car dealership when everything is on sale marked 90% off!” Such an outlook helped the investor make 646% gains in AXP, 700% gains in SBUX, 459% gains in AN, and 235% gains in FDS, among some other winners. Clearly, Dylan has devoted his entire career to this space, and he is staying the course with his flagship product, Behind the Markets. If the founder, CEO, and editor has anything to say, it’s this: “I believe the best investment opportunities are found where Wall Street isn’t looking.”
Access insider investment tips!
Final Verdict
Ultimately, Dylan Jovine is keeping his eyes on a tiny biotech company that is poised to revolutionize cancer treatments. Existing treatments have been demonstrated to attack cancerous and healthy cells, which is the main reason why side effects are supposedly so prevalent. It also doesn’t help that conventional treatment methods are inferior to later-stage cancers. This is all about to change thanks to Smart Chemo, which, in clinical trials, is said to have been effective at focusing only on cancerous cells. As per Dylan himself, he’s calling the shots quite early in the company’s journey only because of the success the new treatment method has had in its trials.
Moreover, with the FDA fast-tracking approval, not to forget the number of established pharmaceuticals watching their every move, he sees more upside than the contrary. By becoming a member of Behind the Markets, individuals will have access to all of Dylan’s research, both on the treatment and expert discussions and the steps to creating a position for maximum gains. One thing to point out at this point is that Dylan is a conservative investor who likes to hold a position over the long term. So, if the aforesaid doesn’t align with one’s respective investing principles, then this isn’t the membership to go after.
All-in-all, our editorial team was persuaded by Dylan’s decades of experience analyzing stocks (especially in the biotech sectors) as well as the financial accessibility presented. Depending on one’s budget and willingness to learn, Dylan has created different memberships, allowing everyone to find an entry that works. Then there’s the money-back guarantee, which makes the Behind the Markets membership virtually risk-free.
Take action on cancer treatment now!
